Hormone therapyFDA-approvedAdjuvant
Aromasin (Exemestane)
Generic name: exemestane
How it works
Blocks the production of estrogen, which can fuel the growth of hormone receptor-positive breast cancer cells.
Cancer types
Breast Cancer— Hormone receptor-positive
Efficacy
In clinical trials, around 90% of hormone receptor-positive patients achieved a complete or partial response, with median overall survival of approximately 25 months.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| New Combination Therapy Shows Promise in Treating Triple-Negative Breast Cancer | Breast Cancer | lab-study | The combination of Olaparib and Exemestane was able to achieve enhanced tumor growth inhibition in a murine xenograft model, greater than either drug employed as a single agent. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.